Delivery Order SPE2DB22D1202-SPE2DB25FVKA1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,042.70. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,943.88. This is a non-set-aside competitive award with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract value of $5,729.56. This is a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100 count units). This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,517.96 and an ultimate completion date of August 26, 2025. The contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,253.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Vyvanse 10 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $15,024.87. This is a child contract with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $1,231.76. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and no set-aside designation was applied. The award represents a competitive procurement executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,467.94 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitive award, structured as a firm fixed-price delivery order with no set-aside designation, is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen Drug Corp's...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVKA1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract ceiling value of $3,982.75. This is a firm fixed price delivery order with no set-aside designation, issued competitively under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across the Defense Health Agency and military healthcare systems. The company's DLA prime contract vehicle enables supply of a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally. This delivery order for Vyvanse, a prescription stimulant medication, represents one component of the company's ongoing pharmaceutical supply operations supporting federal defense and healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 9/2/25 |